Mitogen-activated protein kinase

Jump to: navigation, search
The mitogen-activated protein kinase (MAPK) pathway.[1][2][3][4][5][6][7][8][9]

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mitogen-activated protein (MAP) kinases (EC 2.7.11.24) are serine/threonine-specific protein kinases that respond to extracellular stimuli (mitogens) and regulate various cellular activities, such as gene expression, mitosis, differentiation, cell survival, and apoptosis.[10]

Function

MAPK is involved in the action of most nonnuclear oncogenes. It is responsible for cell response to growth factors such as BDNF or nerve growth factor. Extracellular stimuli lead to activation of a MAP kinase via a signaling cascade ("MAPK cascade") composed of MAP kinase, MAP kinase kinase (MKK or MAP2K), and MAP kinase kinase kinase (MKKK or MAP3K, EC 2.7.11.25).

A MAP3K that is activated by extracellular stimuli phosphorylates a MAP2K on its serine and threonine residues, and then this MAP2K activates a MAP kinase through phosphorylation on its serine and tyrosine residues. This MAP kinase signaling cascade has been evolutionarily well-conserved from yeast to mammals.

MAP kinase activation
Mitogen
MAP kinase kinase kinase

(MAP3K or MKKK)

MAP kinase kinase

(MAP2K or MKK)

MAP kinase
further signalling

WikiDoc Resources for Mitogen-activated protein kinase

Articles

Most recent articles on Mitogen-activated protein kinase

Most cited articles on Mitogen-activated protein kinase

Review articles on Mitogen-activated protein kinase

Articles on Mitogen-activated protein kinase in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mitogen-activated protein kinase

Images of Mitogen-activated protein kinase

Photos of Mitogen-activated protein kinase

Podcasts & MP3s on Mitogen-activated protein kinase

Videos on Mitogen-activated protein kinase

Evidence Based Medicine

Cochrane Collaboration on Mitogen-activated protein kinase

Bandolier on Mitogen-activated protein kinase

TRIP on Mitogen-activated protein kinase

Clinical Trials

Ongoing Trials on Mitogen-activated protein kinase at Clinical Trials.gov

Trial results on Mitogen-activated protein kinase

Clinical Trials on Mitogen-activated protein kinase at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mitogen-activated protein kinase

NICE Guidance on Mitogen-activated protein kinase

NHS PRODIGY Guidance

FDA on Mitogen-activated protein kinase

CDC on Mitogen-activated protein kinase

Books

Books on Mitogen-activated protein kinase

News

Mitogen-activated protein kinase in the news

Be alerted to news on Mitogen-activated protein kinase

News trends on Mitogen-activated protein kinase

Commentary

Blogs on Mitogen-activated protein kinase

Definitions

Definitions of Mitogen-activated protein kinase

Patient Resources / Community

Patient resources on Mitogen-activated protein kinase

Discussion groups on Mitogen-activated protein kinase

Patient Handouts on Mitogen-activated protein kinase

Directions to Hospitals Treating Mitogen-activated protein kinase

Risk calculators and risk factors for Mitogen-activated protein kinase

Healthcare Provider Resources

Symptoms of Mitogen-activated protein kinase

Causes & Risk Factors for Mitogen-activated protein kinase

Diagnostic studies for Mitogen-activated protein kinase

Treatment of Mitogen-activated protein kinase

Continuing Medical Education (CME)

CME Programs on Mitogen-activated protein kinase

International

Mitogen-activated protein kinase en Espanol

Mitogen-activated protein kinase en Francais

Business

Mitogen-activated protein kinase in the Marketplace

Patents on Mitogen-activated protein kinase

Experimental / Informatics

List of terms related to Mitogen-activated protein kinase

Groups

To date, six distinct groups of MAPKs have been characterized in mammals:

  1. extracellular signal-regulated kinases (ERK1, ERK2). The ERKs (also known as classical MAP kinases) signaling pathway is preferentially activated in response to growth factors and phorbol ester (a tumor promoter), and regulates cell proliferation and cell differentiation.
  2. c-Jun N-terminal kinases (JNKs), (MAPK8,MAPK9,MAPK10) also known as stress-activated protein kinases (SAPKs).
  3. p38 isoforms. (MAPK11, MAPK12(= ERK6), MAPK13, MAPK14) Both JNK and p38 signaling pathways are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.
  4. ERK5. ERK5 (MAPK7), which has been found recently, is activated both by growth factors and by stress stimuli, and it participates in cell proliferation.
  5. ERK3/4. ERK3 (MAPK6) and ERK4 (MAPK4) are structurally related atypical MAPKs posses SEG motif in activation loop and displaying major differences only in the C-terminal extension. ERK3 and ERK4 mostly cytoplasmic protein which binds, translocates and activates the MK5 (PRAK, MAP2K5). ERK3 is known as an unstable unlike ERK4 which is relativily stable.[11]
  6. ERK7/8. (MAPK15) This is newest member of MAPKs and behaves like atypical MAPKs. It possesses a long C terminus similar to ERK3/4.

See also

References

  1. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999). "Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms". Science. 286 (5443): 1358–62. PMID 10558990. doi:10.1126/science.286.5443.1358. 
  2. Chadee DN, Yuasa T, Kyriakis JM (2002). "Direct activation of mitogen-activated protein kinase kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2". Mol. Cell. Biol. 22 (3): 737–49. PMID 11784851. doi:10.1128/MCB.22.3.737-749.2002. 
  3. Chang L, Karin M (2001). "Mammalian MAP kinase signalling cascades". Nature. 410 (6824): 37–40. PMID 11242034. doi:10.1038/35065000. 
  4. Chen YR, Tan TH (2000). "The c-Jun N-terminal kinase pathway and apoptotic signaling (review)". Int. J. Oncol. 16 (4): 651–62. PMID 10717232. 
  5. Hazzalin CA, Mahadevan LC (2002). "MAPK-regulated transcription: a continuously variable gene switch?". Nat. Rev. Mol. Cell Biol. 3 (1): 30–40. PMID 11823796. doi:10.1038/nrm715. 
  6. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD (1997). "BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C". EMBO J. 16 (23): 7054–66. PMID 9384584. doi:10.1093/emboj/16.23.7054. 
  7. Kiefer F, Tibbles LA, Anafi M, Janssen A, Zanke BW, Lassam N, Pawson T, Woodgett JR, Iscove NN (1996). "HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway". EMBO J. 15 (24): 7013–25. PMID 9003777. 
  8. Pearson G, English JM, White MA, Cobb MH (2001). "ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation". J. Biol. Chem. 276 (11): 7927–31. PMID 11118448. doi:10.1074/jbc.M009764200. 
  9. Weston CR, Lambright DG, Davis RJ (2002). "Signal transduction. MAP kinase signaling specificity". Science. 296 (5577): 2345–7. PMID 12089430. doi:10.1126/science.1073344. 
  10. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH (2001). "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions". Endocr. Rev. 22 (2): 153–83. PMID 11294822. doi:10.1210/er.22.2.153. 
  11. Kant S, Schumacher S, Singh MK, Kispert A, Kotlyarov A, Gaestel M. (2006). "Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5.". J Biol Chem. 281 (46): 35511–9. PMID 16973613. doi:10.1074/jbc.M606693200. 

External links

de:MAP-Kinaseur:انقسامیہ مفاعل لحمیاتی حرمرہ

Linked-in.jpg